ChargePoint Technology Industry Blog
A growing demand for highly potent active pharmaceutical ingredients (HPAPIs), twinned with the prevalence of oncological, immunosuppressant and hormone-based products is fuelling need for high potency handling capabilities.
ChargePoint Technology's very own Michael Avraam discusses the potential issues with containment performance testing, data collection and interpretation and how these may affect end user with Pharma Focus Asia. You can read the full article (pg.50) here.
We will be showcasing at Achema from 11th-15th June. Visit us in hall 3.0, Stand D14 to view our range of containment valves and get a sneak preview of our new technology, VERIFI.
ChargePoint are the market leaders in powder containment and aseptic transfer valves. We can provide you with operator safety and sterility assurance for pharmaceutical, biotech, chemical and other process industries.
With the demand in high potency containment systems continuing to rise, it has never been more critical to have adequate containment strategies and appropriate verification in place. Yet, it is also crucial to understand the variations in validation testing available and the potential challenges and differences posed by the interpretation of results.
Our global product manager, Michael Avraam speaks to European Pharmaceutical Manufacturer about the considerations surrounding containment performance testing and data collection methods. Michael also discusses the techniques available to help ensure efficient containment performance testing moving forward. You can read the full article in EPM here.
INTERPHEX 2018 is just around the corner and in the lead up, ChargePoint Inc's president Chris Rombach has gathered with other industry experts in the latest pre-show blog to discuss the challenges and opportunities facing the industry in 2018.
With the rising demand for manufacturing using highly potent active pharmaceutical ingredients (HPAPIs) being a huge trend in the industry, Chris talks about the flourishing biotech and oncology markets as well as the increase in 'virtual' pharmaceutical companies and their impact. He also discusses how the containment sector is expected to grow alongside this demand, as high potency manufacturers search for the best containment strategy. Ultimately, this means that more innovative solutions are coming to the market, particularly that of SMART monitoring technology.
Ensuring a safe and sterile environment for active pharmaceutical ingredients (APIs) and formulation ingredients is fundamental during aseptic processing. Air filtration systems, materials transfer and of course operators themselves bring an abundance of potential hazards during the manufacturing process. Therefore there have been many techniques developed in order to provide a risk-averse and contamination-free environment for production.
ChargePoint Technology's global product manager, Christian Dunne discusses the various techniques available with Pharmaceutical Manufacturing. From barrier technologies such as isolators and RABS to split butterfly valve technology (SBV), Christian weighs up the benefits of each and their place within the sector. You can read the full article here